No abnormal bowel activities (no oily stools, no diarrhoea) were recorded in the treated group, as it is the case with the commonly prescribed anti-obesity drug, pancreatic lipase inhibitor, Orlistat® at the required dosage of 120 mg, three times a day. This evidence concerns the gene PNLIP and obesity disorder.